Zdeněk Ráčil

9.2k total citations · 1 hit paper
81 papers, 1.7k citations indexed

About

Zdeněk Ráčil is a scholar working on Hematology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Zdeněk Ráčil has authored 81 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hematology, 33 papers in Infectious Diseases and 27 papers in Epidemiology. Recurrent topics in Zdeněk Ráčil's work include Antifungal resistance and susceptibility (29 papers), Acute Myeloid Leukemia Research (22 papers) and Fungal Infections and Studies (20 papers). Zdeněk Ráčil is often cited by papers focused on Antifungal resistance and susceptibility (29 papers), Acute Myeloid Leukemia Research (22 papers) and Fungal Infections and Studies (20 papers). Zdeněk Ráčil collaborates with scholars based in Czechia, Germany and Slovakia. Zdeněk Ráčil's co-authors include Jiřı́ Mayer, Martina Lengerová, Iva Kocmanová, Barbora Weinbergerová, Jana Winterová, Martina Tošková, Oliver A. Cornely, Shahid Husain, Yasuhito Nannya and Dimitra Mitsani and has published in prestigious journals such as Blood, PLoS ONE and Journal of Clinical Microbiology.

In The Last Decade

Zdeněk Ráčil

78 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia

2018 246 citations Johan Maertens, Corrado Girmenia et al. Journal of Antimicrobial Chemotherapy profile →

Peers

Countries citing papers authored by Zdeněk Ráčil

Since Specialization

Citations

This map shows the geographic impact of Zdeněk Ráčil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zdeněk Ráčil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zdeněk Ráčil more than expected).

Fields of papers citing papers by Zdeněk Ráčil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zdeněk Ráčil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zdeněk Ráčil. The network helps show where Zdeněk Ráčil may publish in the future.

Co-authorship network of co-authors of Zdeněk Ráčil

This figure shows the co-authorship network connecting the top 25 collaborators of Zdeněk Ráčil. A scholar is included among the top collaborators of Zdeněk Ráčil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zdeněk Ráčil. Zdeněk Ráčil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comprehensive management of sickle cell disease in rural Uganda: a model of integrated care 2025 ·The Lancet Haematology ·(unknown), Shafaqat Ali, (unknown), (unknown), (unknown), (unknown), Zdeněk Ráčil	1
2	Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia 2022 ·Cancer Immunology Immunotherapy ·Andrea Knight, Martin Piskáček, Michal Jurajda, Jiřina Procházková, Zdeněk Ráčil, Daniela Žáčková, Jiřı́ Mayer	3
3	A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel 2022 ·Clinical Epigenetics ·(unknown), (unknown), Cyril Šálek, (unknown), (unknown), (unknown), Jiřı́ Mayer, Zdeněk Ráčil, Petr Cetkovský, (unknown)	5
4	Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells 2021 ·Annals of Hematology ·Julian Baumeister, Tiago Maié, Nicolas Chatain, Lin Gan, Barbora Weinbergerová, Marcelo A. S. Toledo, Jörg Eschweiler, Angela Maurer, Jiřı́ Mayer, Blanka Kubešová, Zdeněk Ráčil, Andreas Schuppert, Ivan G. Costa, Steffen Koschmieder, Tim H. Brümmendorf, Deniz Gezer	8
5	European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia breakdown → 2018 ·Journal of Antimicrobial Chemotherapy ·Johan Maertens, Corrado Girmenia, Roger J. M. Brüggemann, Rafael F. Duarte, Christopher C. Kibbler, Per Ljungman, Zdeněk Ráčil, Patricia Ribaud, Monica A. Slavin, Oliver A. Cornely, J. Peter Donnelly, Catherine Cordonnier, (unknown)	246
6	The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice 2018 ·Journal of Cancer Research and Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Tomáš Loja, Nikola Tom, Vojtěch Bystrý, (unknown), Dana Dvořáková, Jiřı́ Mayer, Zdeněk Ráčil	5
7	FungiScope^™—Global Emerging Fungal Infection Registry 2017 ·Mycoses ·Danila Seidel, Luisa Durán Graeff, Maria J. G. T. Vehreschild, Hilmar Wisplinghoff, Maren Ziegler, Jörg Janne Vehreschild, Blasius Liss, Axel Hamprecht, Philipp Köhler, Zdeněk Ráčil, Н Н Климко, Donald C. Sheppard, Raoul Herbrecht, Anuradha Chowdhary, Oliver A. Cornely, (unknown)	31
8	Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Jan Vydra, Cyril Šálek, Jiřı́ Schwarz, Pavel Žák, Jan Novák, (unknown), (unknown), Jiřı́ Mayer, Petr Cetkovský, Zdeněk Ráčil	2
9	Incorporation of humanized niche as a strategy for improvingleukemic engraftment in immunodeficient mice 2015 ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jiřı́ Mayer, Zdeněk Ráčil	2
10	Detecting human cytomegalovirus drug resistant mutations and monitoring the emergence of resistant strains using real-time PCR 2014 ·Journal of Clinical Virology ·(unknown), Martina Lengerová, (unknown), Dana Dvořáková, (unknown), (unknown), Barbora Weinbergerová, Jiřı́ Mayer, Zdeněk Ráčil	8
11	Význam fyzické aktivity u pacientů s hematoonkologickými malignitami 2012 ·Andrea Janíková, (unknown), (unknown), Ladislav Baťalík, (unknown), Daniela Žáčková, Zdeněk Ráčil, Jiřı́ Mayer	2
12	Reactivity of the 1,3‐β‐D‐glucan assay during bacteraemia: limited evidence from a prospective study 2012 ·Mycoses ·Zdeněk Ráčil, Iva Kocmanová, Martina Tošková, Jana Winterová, Martina Lengerová, (unknown), Jiřı́ Mayer	17
13	Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia withNPM1mutations 2012 ·Leukemia & lymphoma ·Dana Dvořáková, Zdeněk Ráčil, Marek Borský, (unknown), (unknown), Filip Rázga, Martina Lengerová, Jiřı́ Mayer	2
14	Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations 2012 ·Molecular Diagnosis & Therapy ·Filip Rázga, Tomáš Jurček, Daniela Žáčková, Dana Dvořáková, Martina Tošková, (unknown), Jiřı́ Mayer, Zdeněk Ráčil	5
15	Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics 2012 ·Leukemia & lymphoma ·Zdeněk Ráčil, Martina Tošková, Iva Kocmanová, Lucie Burešová, Michal Kouba, Ľuboš Drgoňa, Lucia Masárová, (unknown), Elena Tóthová, (unknown), Kristina Forsterová, (unknown), (unknown), (unknown), (unknown), (unknown), Petr Cetkovský, Jiřı́ Mayer	5
16	Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy 2011 ·BMC Medical Research Methodology ·Tomáš Pavlík, Eva Janoušová, Zdeněk Pospı́šil, Jan Mužı́k, Daniela Žáčková, Zdeněk Ráčil, Hana Klamová, Petr Cetkovský, Marek Trněný, Jiřı́ Mayer, Ladislav Dušek	4
17	Monitoring of minimal residual disease in acute myeloidleukemia with frequent and rare patient-specific NPM1 mutations 2010 ·American Journal of Hematology ·Dana Dvořáková, Zdeněk Ráčil, (unknown), (unknown), (unknown), Martina Lengerová, Filip Rázga, Jiřı́ Mayer	4
18	Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient‐specific NPM1 mutations 2010 ·American Journal of Hematology ·Dana Dvořáková, Zdeněk Ráčil, (unknown), (unknown), (unknown), Martina Lengerová, Filip Rázga, Jiřı́ Mayer	28
19	Imatinib as the first‐line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials? 2010 ·American Journal of Hematology ·Daniela Žáčková, Hana Klamová, Ladislav Dušek, Jan Mužı́k, Kateřina Machová Poláková, Jana Moravcová, Tomáš Jurček, Dana Dvořáková, Zdeněk Ráčil, Zdeněk Pospı́šil, Alexandra Oltová, K Michalová, Jana Březinová, Filip Rázga, Michael Doubek, Petr Cetkovský, Marek Trněný, Jiřı́ Mayer	12
20	Real-Time PCR Diagnostics Failure Caused by Nucleotide Variability within Exon 4 of the Human Cytomegalovirus Major Immediate-Early Gene 2007 ·Journal of Clinical Microbiology ·Martina Lengerová, Zdeněk Ráčil, (unknown), (unknown), (unknown), Dana Dvořáková, Jiří Vorlíček, Jiřı́ Mayer	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact